JP7697943B2 - 導入遺伝子発現のｄｒｇ特異的低減のための組成物 - Google Patents

導入遺伝子発現のｄｒｇ特異的低減のための組成物 Download PDF

Info

Publication number
JP7697943B2
JP7697943B2 JP2022524118A JP2022524118A JP7697943B2 JP 7697943 B2 JP7697943 B2 JP 7697943B2 JP 2022524118 A JP2022524118 A JP 2022524118A JP 2022524118 A JP2022524118 A JP 2022524118A JP 7697943 B2 JP7697943 B2 JP 7697943B2
Authority
JP
Japan
Prior art keywords
sequence
seq
hidua
nucleotides
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524118A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021081217A5 (https=
JP2022553406A (ja
JP2022553406A5 (https=
Inventor
オルドー，ジュリエット
ウイルソン，ジェームス・エム
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/067872 external-priority patent/WO2020132455A1/en
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2022553406A publication Critical patent/JP2022553406A/ja
Publication of JPWO2021081217A5 publication Critical patent/JPWO2021081217A5/ja
Publication of JP2022553406A5 publication Critical patent/JP2022553406A5/ja
Application granted granted Critical
Publication of JP7697943B2 publication Critical patent/JP7697943B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2022524118A 2019-10-23 2020-10-22 導入遺伝子発現のｄｒｇ特異的低減のための組成物 Active JP7697943B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962924970P 2019-10-23 2019-10-23
US62/924,970 2019-10-23
US201962934915P 2019-11-13 2019-11-13
US62/934,915 2019-11-13
USPCT/US2019/067872 2019-12-20
PCT/US2019/067872 WO2020132455A1 (en) 2018-12-21 2019-12-20 Compositions for drg-specific reduction of transgene expression
US202062972404P 2020-02-10 2020-02-10
US62/972,404 2020-02-10
US202063005894P 2020-04-06 2020-04-06
US63/005,894 2020-04-06
US202063023602P 2020-05-12 2020-05-12
US63/023,602 2020-05-12
US202063038514P 2020-06-12 2020-06-12
US63/038,514 2020-06-12
US202063043600P 2020-06-24 2020-06-24
US63/043,600 2020-06-24
PCT/US2020/056881 WO2021081217A1 (en) 2019-10-23 2020-10-22 Compositions for drg-specific reduction of transgene expression

Publications (4)

Publication Number Publication Date
JP2022553406A JP2022553406A (ja) 2022-12-22
JPWO2021081217A5 JPWO2021081217A5 (https=) 2023-10-18
JP2022553406A5 JP2022553406A5 (https=) 2023-10-18
JP7697943B2 true JP7697943B2 (ja) 2025-06-24

Family

ID=75620360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524118A Active JP7697943B2 (ja) 2019-10-23 2020-10-22 導入遺伝子発現のｄｒｇ特異的低減のための組成物

Country Status (8)

Country Link
US (1) US20220389457A1 (https=)
EP (1) EP4048785A4 (https=)
JP (1) JP7697943B2 (https=)
KR (1) KR20220105158A (https=)
AU (1) AU2020369570A1 (https=)
CA (1) CA3155154A1 (https=)
IL (1) IL292372A (https=)
WO (1) WO2021081217A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230304034A1 (en) * 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
BR112023003310A2 (pt) * 2020-08-24 2023-05-02 Univ Pennsylvania Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas
AU2022369293A1 (en) * 2021-10-18 2024-05-16 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
CA3236188A1 (en) * 2021-10-27 2023-05-04 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
EP4551253A1 (en) * 2022-07-08 2025-05-14 Ospedale San Raffaele S.r.l. Transgene cassettes
CN116064593B (zh) * 2023-02-09 2024-05-14 四川大学 一种毛白杨pgag基因及其应用
US20250276095A1 (en) * 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515831A (ja) 2013-04-11 2016-06-02 ジェネトン 選択的遺伝子治療発現系
JP2018515615A (ja) 2015-05-15 2018-06-14 アール． スコット マカイバー 中枢神経系への治療的送達のためのアデノ随伴
WO2019010335A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania AAV9 MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
IL248102B (en) * 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
EP3411488A1 (en) * 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
KR20180109945A (ko) * 2016-02-22 2018-10-08 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ｍｐｓ ｉ－ 연관 실명의 치료를 위한 ａａｖ－ｉｄｕａ 벡터
SG11202002276VA (en) * 2017-09-20 2020-04-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515831A (ja) 2013-04-11 2016-06-02 ジェネトン 選択的遺伝子治療発現系
JP2018515615A (ja) 2015-05-15 2018-06-14 アール． スコット マカイバー 中枢神経系への治療的送達のためのアデノ随伴
WO2019010335A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania AAV9 MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human Gene Therapy，2019年06月10日，Vol.30，p.957-966
Neuroscience，2009年，Vol. 164，p. 711-723

Also Published As

Publication number Publication date
JP2022553406A (ja) 2022-12-22
IL292372A (en) 2022-06-01
EP4048785A1 (en) 2022-08-31
US20220389457A1 (en) 2022-12-08
KR20220105158A (ko) 2022-07-26
EP4048785A4 (en) 2024-03-27
WO2021081217A1 (en) 2021-04-29
AU2020369570A1 (en) 2022-05-12
CA3155154A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP7697943B2 (ja) 導入遺伝子発現のｄｒｇ特異的低減のための組成物
JP7670759B2 (ja) ムコ多糖症ｉ型を治療するための遺伝子治療
US20260049335A1 (en) Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
TWI835747B (zh) 用於治療黏多醣病 ii 型之基因治療
CA3019427A1 (en) Gene therapy for treating mucopolysaccharidosis type ii
US20230270884A1 (en) Compositions useful for treatment of charcot-marie-tooth disease
JP2023526310A (ja) 導入遺伝子発現のｄｒｇ特異的低減のための組成物
CN113438954A (zh) 可用于治疗gm1神经节苷脂病的组合物
US20240425882A1 (en) Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
TW202045728A (zh) 用於治療克拉培氏病之組成物
US20230167455A1 (en) Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
US20240115733A1 (en) Compositions and methods for treatment of niemann pick type a disease
AU2024320694A1 (en) Compositions and methods for treatment of spinal muscular atrophy
JP2024546578A (ja) ムコ多糖症ｉｉｉａ型の治療のための遺伝子療法
CN118574935A (zh) 用于治疗iiia型粘多糖贮积病的基因疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250612

R150 Certificate of patent or registration of utility model

Ref document number: 7697943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150